Cholangiocarcinoma Diagnosis and Treatment Strategies

Cholangiocarcinoma encompasses a group of highly heterogeneous biliary tract tumours that arise at varying sites along the biliary tree, including intrahepatic, perihilar and distal locations. The insidious onset and nonspecific clinical presentation often delay diagnosis until advanced stages, when curative surgical options are limited. Conventional imaging modalities—including ultrasonography, computed tomography and magnetic resonance cholangiopancreatography—are complemented by histopathological confirmation and emerging liquid-biopsy approaches. At the molecular level, cholangiocarcinomas display diverse genetic and epigenetic alterations, notably fibroblast growth factor receptor 2 (FGFR2) fusions and isocitrate dehydrogenase (IDH) mutations in intrahepatic subtypes. Such insights have facilitated the development of targeted agents and immunotherapy combinations, transforming the therapeutic landscape. First-line systemic regimens remain centred on platinum-based chemotherapy, but the advent of molecular stratification has introduced FGFR and IDH inhibitors, as well as immune checkpoint blockade, into clinical practice. Despite these advances, overall survival remains modest, underscoring the need for improved early detection, refined biomarker panels and integrated multimodal strategies that combine surgery, locoregional treatments and tailored systemic therapy. Ongoing efforts aim to define predictive biomarkers, enhance drug delivery through nanotechnology and exploit the tumour microenvironment to overcome resistance mechanisms.

Research from Nature Portfolio

Recent expert analyses have critically evaluated the classification and molecular underpinnings of cholangiocarcinoma, emphasising the importance of anatomical and cellular origin in guiding management. A comprehensive review in 2020 outlined the genomic, epigenetic and transcriptomic heterogeneity of these tumours and highlighted biomarker discovery initiatives poised to refine diagnosis and prognostication. A 2021 primer further detailed the distinct genetic landscapes of intrahepatic, perihilar and distal cholangiocarcinomas, illustrating how actionable FGFR2 fusions and gain-of-function IDH mutations can be targeted therapeutically. Seminal genomic investigations have also uncovered novel FGFR2–PPHLN1 fusion events and activating mutations in the ARAF oncogene, demonstrating oncogenic potential in functional assays and preclinical models. Together, these studies establish a molecular framework for precision medicine approaches and have spurred the initiation of selective FGFR inhibitors in clinical trials.

Cholangiocarcinoma Diagnosis and Treatment Strategies publication trend

The graph below shows the total number of articles in cholangiocarcinoma diagnosis and treatment strategies across all publications each year (not limited to Nature Index journals).

Technical terms

Cholangiocarcinoma: Malignant adenocarcinoma of the biliary epithelium, classified by anatomical origin.

Intrahepatic cholangiocarcinoma (ICC): Tumour arising within the liver bile ducts.

FGFR2 fusion: Chromosomal rearrangement creating constitutively active fibroblast growth factor receptor 2, amenable to targeted inhibition.

IDH mutation: Gain-of-function alteration in isocitrate dehydrogenase that generates oncometabolites and may be targeted by specific inhibitors.

GEMOX: Chemotherapy regimen combining gemcitabine and oxaliplatin.

FOLFOX: Chemotherapy regimen combining folinic acid, fluorouracil and oxaliplatin.

References

1. Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study. Signal Transduction and Targeted Therapy (2023).
2. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nature Reviews Gastroenterology & Hepatology (2020).
3. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. British Journal of Cancer (2010).
4. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. The Lancet Oncology (2021).
5. Cholangiocarcinoma. Nature Reviews Disease Primers (2021).
6. Massive parallel sequencing uncovers actionable FGFR2–PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma. Nature Communications (2015).
7. Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma. British Journal of Cancer (2018).